Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.48 USD
-0.03 (-1.99%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.49 +0.01 (0.68%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Reneo Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -77.39 | -51.96 | -39.77 | -19.47 | -12.44 |
Depreciation/Amortization & Depletion | -3.96 | -0.73 | 0.25 | 0.02 | -0.12 |
Net Change from Assets/Liabilities | 12.22 | 0.96 | -2.80 | 0.51 | -1.02 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.45 | 4.36 | 4.34 | 0.40 | 1.06 |
Net Cash From Operating Activities | -63.68 | -47.36 | -37.98 | -18.54 | -12.51 |
Property & Equipment | -0.22 | -0.35 | -0.20 | -0.02 | -0.01 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 10.74 | -57.50 | -23.18 | 7.40 | -7.23 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 10.52 | -57.84 | -23.38 | 7.38 | -7.24 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -4.40 | 0.28 | 47.79 | 47.27 | 24.99 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 65.27 | 0.19 | 84.61 | 0.00 | 0.00 |
Net Cash from Financing Activities | 60.87 | 0.47 | 132.41 | 47.27 | 24.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 7.71 | -104.73 | 71.05 | 36.11 | 5.24 |
Cash at Beginning of Period | 19.93 | 124.66 | 53.61 | 17.50 | 12.27 |
Cash at End of Period | 27.63 | 19.93 | 124.66 | 53.61 | 17.50 |
Diluted Net EPS | -2.52 | -2.12 | -2.19 | -9.60 | NA |
Fiscal Year End for Reneo Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -8.43 | -77.39 | -53.83 | -34.64 |
Depreciation/Amortization & Depletion | NA | -0.89 | -3.96 | -3.43 | -1.93 |
Net Change from Assets/Liabilities | NA | -12.86 | 12.22 | 8.14 | 7.95 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1.16 | 5.45 | 5.19 | 3.46 |
Net Cash From Operating Activities | NA | -21.01 | -63.68 | -43.93 | -25.16 |
Property & Equipment | NA | 0.00 | -0.22 | -0.20 | -0.18 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 13.76 | 10.74 | -29.06 | -50.33 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 13.76 | 10.52 | -29.25 | -50.50 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 0.00 | -4.40 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 65.27 | 64.99 | 64.82 |
Net Cash from Financing Activities | NA | 0.00 | 60.87 | 64.99 | 64.82 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -7.26 | 7.71 | -8.19 | -10.85 |
Cash at Beginning of Period | NA | 27.63 | 19.93 | 19.93 | 19.93 |
Cash at End of Period | NA | 20.38 | 27.63 | 11.74 | 9.08 |
Diluted Net EPS | NA | -0.25 | -0.70 | -0.57 | -0.65 |